Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Project description

Decreasing resistance to an important treatment for tuberculosis

Fields of science

• medical and health sciences › clinical medicine › pneumology › tuberculosis

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
• H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

• IMI2-2018-16-06 - Functional Ethionamide boosters: a novel combination for tuberculosis therapy

Call for proposal

H2020-JTI-IMI2-2018-16-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

BIOVERSYS AG

Address

Hochbergerstrasse 60 C Technologiepark Basel
4057 Basel
Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 6 926 375

Participants (1)

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

Spain

EU contribution

€ 0

Address

C/ Severo Ochoa Numero 2 Parque Tecnologico De Mad
28760 Tres Cantos Madrid

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)